Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. In addition, it provides non-surgical product technologies. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.
Over the last 12 months, insiders at Femasys Inc. have bought $0 and sold $0 worth of Femasys Inc. stock.
On average, over the past 5 years, insiders at Femasys Inc. have bought $2.6M and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,000 shares for transaction amount of $9,950 was made by Dyett John () on 2021‑06‑23.
2021-06-23 | 1,000 0.0459% | $9.95 | $9,950 | -61.10% | ||||
2021-06-22 | director | 100,000 6.2919% | $13.00 | $1.3M | -58.84% | |||
2021-06-22 | 40,000 2.5168% | $13.00 | $520,000 | -58.84% | ||||
2021-06-22 | director | 40,000 2.5168% | $13.00 | $520,000 | -58.84% | |||
2021-06-22 | director | 7,000 0.4404% | $13.00 | $91,000 | -58.84% | |||
2021-06-18 | 12,500 0.6491% | $12.94 | $161,750 | -65.46% |
Uzialko Edward R | director | 127786 0.5581% | $1.12 | 1 | 0 | <0.0001% |
Dyett John | 114709 0.5009% | $1.12 | 3 | 0 | <0.0001% | |
Adams John Q JR | director | 40000 0.1747% | $1.12 | 1 | 0 | <0.0001% |
Larsen Charles | director | 7000 0.0306% | $1.12 | 1 | 0 | <0.0001% |